chrisvoncsefalvay/vaers-outcomes huggingface dataset:
slight shortness of breath in the next few minutes; chest and back tightness began; chest and back tightness began; rash and hives across my face; rash and hives across my face; This is a spontaneous report from a contactable Nurse (patient). A 24-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: EL9262 and expiration date was not reported), via unspecified route of administration in left arm on 26Jan2021 at 05:00 PM, as single dose for COVID-19 immunisation. The patient's medical history included GERD, migraines, depression, anxiety and allergy to peanuts and codeine. The concomitant medication included Amitriptyline, lansoprazole, Zyrtec and multivitamin. The historical vaccine included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: EL0142 and expiration date was not reported), in left arm on 03Jan2021 at 03:30 PM for COVID-19 immunisation. On 26Jan2021 at 17:05 patient experienced chest and back tightness began and slight shortness of breath in the next few minutes. Reported symptoms to on duty nurses who immediately laid down and checked vitals. BP 138/98, P 102, O2 98. On 26Jan2021 at 17:00 Nurses reported that she had broken out into a rash and hives across her face and chest. Given O2 at 2 Liters per minute. She was taken to the ER and given a steroid nebulizer, benadryl and claritin. Discharged and prescribed 20mg prednisone QD (every day) for 5 days, and a pro-air albuterol inhaler prn (as needed). Facility type vaccine: Doctor's office/urgent care. The patient did not other vaccine in four weeks. The adverse event resulted in emergency room/department or urgent care visit. The patient received corrective treatment for the adverse events. No COVID prior vaccination and no covid tested post vaccination. The outcome of the event was recovering.  Follow-up attempts are completed. No further information is expected.
Pain in arm,  fever, chills, stuffy nose, aches in body throughout, insomnia, headache. Still ongoing and seemingly getting worse
Information has been received from a registered nurse concerning a 13 month old white male child with no past medical history, no allergies and who was well at the time of vaccination.  On 11/11/2002 the child was vaccinated intramuscular in the right leg with a first dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation)(Lot # 642233/0232M).  Concomitant medications included vaccination intramuscular in the left leg with a fourth dose of diphtheria toxoid (+) pertussis vaccine (+) tetanus toxoid (DTP VACCINE ADSORBED USP)(Lot # C0947AA) on 11/11/2002 and vaccination intramuscular in the left leg with a fourth dose of Haemophilus B conjugate vaccine (ACTHIB(Haemophilus B conjugate vaccine ))(Lot # UA779AA) on 11/11/2002.  The registered nurse initially reported that on 01/25/2003 the patient developed mumps.  The swelling was unilateral.  As of 02/03/2003 the child still has some swelling but was no longer febrile.  The same nurse reported additional follow up information.  She reported that the mother noticed unspecified symptoms while bathing the child on 01/25/2003 and the patient was seen by the physician on 01/26/2003.  On 01/26/2003 it was noted that the tonsils were mildly enlarged and pink with no exudate.  The area between the left posterior mandible and mastoid had 2 + swelling and slight redness and heat was noted.  "none over mandible" was also reported.  On 01/28/2003 laboratory evaluation revealed that rubella IgG was "immune"; mumps antibodies, IgM was 1.19 (reference ranges noted that > 1.10 was noted to be positive with a note which stated "presence of IgM specified antibody should be interpreted in conjunction with the patient's clinical history and exposure rish when an acute infection is suspected") and mumps antibodies, IgG was 3.95 (reference range noted > or = to 1.10 was positive and a note which stated "presence of antibodies to mumps is presumptive evidence of immunity except when active infection is suspected).  Follow up information from the nurse also noted that on 02/10/2003 the child required an I&D of an abscess over the parotid gland.  Further follow up information from the nurse stated that the child was diagnosed with mumps and the abscess over the parotid gland was secondary to the mumps.  On 04/03/2003 the nurse reported that the patient had recovered.  No further information is expected.
Conscious but dizzy BP/HR dropped. Pt didn't experience sxs until approximately 5 mins after the vaccine was administered. Called for Paramedics. After Paramedics came, BP/HR slowly rose. Normal skin color returned - Heart rhythm was normal. PO2 was normal. He was advised to go home and f/u w/ primary care MD.
dolor fuerte de garganta, dolor de cabeza y al dia siguiente abundante tos y flema por la nariz
2 and 3 days after second shot having extreme dizziness; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FA7488) via an unspecified route of administration in the right arm on an unknown date in Sep2021 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2587) via an unspecified route of administration in the right arm on 08Aug2021 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. On 16Sep2021 at 14:00, 2 and 3 days after second shot, the patient experienced extreme dizziness. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event 2 and 3 days after second shot having extreme dizziness was unknown at the time of the report.
Itching, redness, hot, swelling around injection site. Occurring 2 days after injection. Pharmacist told her to apply hydrocortisone cream to area. If that doesn't work try BENADRYL. Follow up with phone call.
my feet got larger. I was a size 12 and now I have size 15 feet
FEVER, CHILLS, FATIGUE, GENERAL MALAISE, HEADACHE, JOINT ACHE,  ACETAMINOPHEN 250 EVERY 12 HRS ASPIRIN 250 EVERY 12 HRS
I started to feel bad in the afternoon. I had fever and chills for 48 hours. Severe muscle and body aches and joint pain for three days. I very tired and had to lay down. I took Tylenol and Omeprazole for gastric pain. This lasted for a week. Some gastric pain and no appetite and a bitter taste in my mouth. I had no nausea. The second dose was less severe but it lasted 24 hours. I had hip pain which was different. Second dose
Red, hot, hard, and tender area around injection site. Approximately 4 inches high by 3 inches wide.
really bad rash on her body; all over her body;  it comes and goes/it appears on the other parts of her body,  it's in her legs, all over her body; rash that can had her body it got worse like swollen and itching; rash that can had her body it got worse like swollen and itching; This is a spontaneous report from a contactable consumer or other non-HCP. A female patient of an unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EW0173), via an unspecified route of administration on 11May2021 as DOSE 2, SINGLE for covid-19 immunization. Historical vaccine included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution injection, Lot number/Expiration date: Unknown) on an unspecified date for covid-19 immunization and experienced No reaction on previous exposure to drug. The patient's medical history and concomitant medications were not reported. On an unspecified date of May2021 the patient experienced really bad rash on her body; all over her body; it comes, and goes/it appears on the other parts of her body, it's in her legs, all over her body and rash that can had her body it got worse like swollen and itching. The patient underwent lab tests and procedures which included blood test: unknown on an unspecified date. The outcome of event was not recovered.  Follow-up (07Sep2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.  No follow-up attempts are possible. Information about lot/batch no cannot be obtained. No further information is expected.
12 days after 2nd vaccine-started with fever/chills, cervical lymphadenopathy and redness/vesicular type eruption on nose.  Fever/chills persisted through night, followed by 16hr N/V and worsening of eruption- vesicular/pustular  on nose, then with subsequent right facial swelling.
5/6/22 Janssen COVID-19 vaccine administered to LD at 1224. Client and daughter dismissed to the lobby to wait for 15 minutes. After about 5 minutes, this writer was called to the lobby by a clerical staff member. The client was found sitting in a chair laying over the chair next to her with her head down. Client's daughter was sitting in the chair next to her.  Client reported feeling nauseous, light headed and hot. She reported tingling in her fingers. Client appears diaphoretic and white.  This writer assisted client to lay on the floor. Elevated both legs on a chair. Clerical staff got her cold water and a cold, wet paper towel for her forehead. This writer checked client's blood pressure of her right arm, while laying down. 108/68, pulse 81, 98% O2sat.  After laying on the floor for about 3 minutes. Assisted client to rise slowly to standing and brought her back to an exam room to lay down and recover.  Client laid on the exam table for about 20 minutes, drinking water and eating some crackers given to her by this writer. Daughter present the entire time. Husband came to clinic shortly after bringing the client to the exam room.  Client continued to rest and then at about 1300, the client felt well enough to leave and go home. Husband and daughter walked her out to their car.  Before they left, educated client and family on vasovagal response. Informed client that a VAERS report would be completed and that she should notify her PCP of the incident. Verbalized understanding. While the patient was present, PCP called her with a result of a test and she notified them of the situation.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 26-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 08Dec2021 as dose 1, single (Lot number: 32030BD) at the age of 26 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). Concomitant medication(s) included: FLOVENT HFA, start date: Jul2022, stop date: Jul2022. The following information was reported: COVID-19 (medically significant) with onset 17Dec2021, outcome "unknown", described as "COVID 19"; DRUG INEFFECTIVE (medically significant) with onset 17Dec2021, outcome "unknown". The patient underwent the following laboratory tests and procedures: Polymerase chain reaction: Positive, notes: Day 3: Positive rapid and PCR tests; SARS-CoV-2 test: Negative, notes: Day 1: Negative rapid result; Positive, notes: Day 8: Last Paxlovid dose in morning. Prominent positive band for rapid test; Positive, notes: Day 10: Slight positive band for positive result on rapid test; Negative, notes: Day 12:Negative rapid test result; Positive, notes: but had a clear/dark band for positive rapid test 9 days after dose; rebound, notes: Confirmed Covid-19 rebound via rapid test on August 3. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Patient receive Paxlovid as therapeutic measure.
Redness 3.5in x 2.5in, Swelling 3.5 in x 2.5 x 1/8 in, heat, pain to the touch.
Received 2nd vaccine on 3/12/21-reported on 3/15/21 that rash started on 3/13/21 to Right wrist/hand and bilateral thigh to knees Sunday,3/14, reported lower lip was swollen.  Did take Benadryl with resolution of lip swelling on 3/15.  continues with rash today.
Injection site was warm and still tender to the touch. About 3 inch perimeter raised, red and rash-like (persistent 3/19)
Two days after receiving second dose of Shingrix, patient reports developing welts down her left arm and experiencing pain on the trunk of her body below her left armpit .  She later developed shooting pains about every 30 seconds on the right side of her head that later moved to her right jaw and ear canal which lasted approximately 12 hours.  Five days after her vaccination, a red blister-like sore developed on the middle finger of her right hand.  When a second blister developed on the same finger, she was given a prescription for Valtrex from her provider.
4 doses of expired Bexsero were inadvertently administered; This case was reported by a nurse via sales rep and described the occurrence of expired vaccine used in a 17-year-old male patient who received Men B NVS (Bexsero) (batch number ABXA14BA, expiry date March 2021) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 26th April 2021, the patient received Bexsero and Bexsero Pre-Filled Syringe Device. On 26th April 2021, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follow: During a school vaccination clinic, a dose of expired Bexsero was inadvertently administered to the patient, the vaccine was expired in March 2021, which led to expired vaccine used. The reporter consented to follow up. This was one of 4 linked cases reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR094018:same reporter US-GLAXOSMITHKLINE-US2021AMR094020:same reporter US-GLAXOSMITHKLINE-US2021AMR094010:same reporter
Hospitalized;  COVID-19 positive 8.28.21;  admitted for COVID (fully vaccinated - 3 doses of Pfizer vaccine recevied)   Admission Date: 8/29/2021 Discharge Date: 08/30/2021 Admitting Diagnoses: COVID-19 PRESENTING PROBLEM:  COVID-19   HOSPITAL COURSE: Patient is a 87 y.o. man who presented to the emergency department with complaints of cough and shortness of breath.  He has past medical history of chronic obstructive pulmonary disease, OSA with CPAP use, hypertension, hyperlipidemia, SVT, and CKD. Patient  received a COVID-19 booster vaccine on Tuesday, 08/24/2021.  Shortly after that time, he he developed a cough with shortness of breath.  The cough had been worsening which prompted him to present to the emergency department for further evaluation.  He additionally complained of fever, chills, weakness, and sputum production.     In the emergency department, patient was febrile, tachycardic, hypertensive, and required supplemental oxygen to maintain a saturation greater than 90%.  Complete blood count was unremarkable.  BMP showed CKD.  Lactic acid was 1.3.  COVID-19 was positive.  Chest x-ray showed no acute cardiopulmonary disease.  Patient has been transferred and admitted to the hospital for further evaluation and management of COVID-19.   He was started on decadron and remdesivir. His procalcitonin was mildly elevated and was started on rocephin and azithromycin. He was initially requiring supplemental o2 and successfully weaned off. He was discharged home on decadron and azithromycin.
Approximately 6 hours after the vaccination, I experienced a severe tinnitus, or ringing in the left ear.  I have never experience this level of ringing before, although I have had mild and mostly unnoticeable tinnitus for some time. This was many times more severe. While the intensity has settled down somewhat, I now have a constant, unremitting ringing  in my left ear that is loud enough to be bothersome most of the day. It is still many times louder than anything I have experienced before. I had no other noise exposure or out-of-the-ordinary events that might trigger this.
Immediate local reaction of redness and small hives at site of Dtap. Given 12.5 Benadryl. Bp 104/50 lungs clear, Ice applied, no distress of SOB, Seen by DR, F/U call 9/7/06 child fine and attending school.
Developed a R ICA acute thrombus (seen on CTA)  and arrived with significant left sided weakness as a code stroke on 6/5. Received tPA and went for thrombectomy to evaluate the acute R ICA occlusion further which was found to be patent (thought to be due to tPA effect). After tPA, pt has complete resolution of weakness. MRI brain found a R striatum acute infarct.  Pt was on an estrogen oral contraceptive medication, nonsmoker. Healthy with no hematologic conditions (no prior bleeding or clotting issues). No chronic medical conditions and healthy (would run 6 miles a day, etc), on no other medications or over the counter supplements.
c/o twitching/jerking/clammy skin with minimal responsiveness to commands immediately after vaccine administration
pt recvd vax;acted weird, loss appetite & devel milder, unspecified adverse experiences;
This study case was received from the investigator on 25 August 2012. A male subject passed out in formation on 16 August 2012, one day after the subject had received on 15 August 2012 the following vaccines: ACAM2000 (lot number, route and site of administration not reported), an injection of TYPHOID VACCINE (lot number, route and site of administration not reported) and an injection of ANTHRAX VACCINE (lot number, route and site of administration not reported). The subject felt dizzy, lightheaded, short of breath (SOB), blurred vision, sweating and experienced syncope in formation. The subject denied chest pain and cough. Rapid troponin was normal, EKG on 21 August 2012 indicated ST elevation due to early repolarization but not active ischemia, unconcerning for myopericarditis. The subject did not take any medications to treat the SAE. On 21 August 2012, the subject's smallpox injection site was reported to look "horrible". One tube of blood was taken. The subject reports no new concomitant medications (con-meds) and no HURT was marked on Wong Baker scale. The subject reported that fainting was moderate and dizziness, lightheadedness, blurred vision, sweating and shortness of breath was mild. No further information was available at the time of the report. The subject's outcome was recovered on 16 August 2012. According to the investigator, passing out in formation was possibly related to the trial product. Documents held by sender: none.
Sudden onset of Atrial Fibrillation within 2 minutes; This is a spontaneous report from a contactable physician (patient). This 81-years-old male patient received dose 2 of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) Lot number EN6206, on 05Mar2021 10:45 in right arm as a single dose (at the age of 81 years) for COVID-19 immunization.  The patient had dose 1 of BNT162B2 for COVID-19 immunization, Lot number EL9261, on 05Feb2021 10:45, in Left arm.  Relevant medical history included GERD (gastrooesophageal reflux disease).  There were no allergies reported. Concomitant medication included Omeprazole, Ursodiol, fexofenadine hydrochloride (Allegra), diphenhydramine hydrochloride (Benadryl).  The patient had no other vaccine in four weeks.  The patient experienced sudden onset of Atrial Fibrillation within approximately 2 minutes on 05Mar2021 reported as 10:45. The patient was seen at the physician's office.  Treatment included EKG; Xeralto anticoagulant.  The patient did not have COVID prior to vaccination and was not tested post vaccination.  The outcome of sudden onset of Atrial Fibrillation was not recovered.; Sender's Comments: Based on the information currently available, a possible contributory role of the suspect drug in the reported event cannot be completely ruled out given the implied temporal association. However, underlying medical conditions may provide the alternate explanations. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regul atory Authorities, Ethics Committees and Investigators, as appropriate.
Developed Bell's Palsy symptoms on the left side of my face almost exactly 24 hours after vaccine administered
Immediately after receiving the vaccine, I experienced severe left arm pain for a total of 3 days which was relieved only after taking Ibuprofen. About a week later, I started noticing that I would become very tired and short of breath after going up 4 flights of stairs (which I normally do several times a day during work). For the past week, I have been feeling more fatigued and short of breath. I was completely normal before receiving the vaccine and nothing has changed in my diet or daily routine.
Just sort of 2 weeks after vaccine, I started feeling discomfort in my right eye.  Later that week, was diagnosed with ocular shingles, which is very rare for someone my age.
Information has been received from an adult male pt with no known drug allergies and no past medical history who was vaccinated with a dose of pneumococcal vaccine 23 polyvalent. Concomitant therapy included Klonopin. Subsequently the pt experienced burning in his lungs and developed a temperature that "went to 101.8 deg." The reporter indicated that he initially went to a physician and was diagnosed with bronchitis. He later went to his family physician and was told he had bronchitis which might turn into pneumonia. Follow-up info was received from the pt's family physician indicating that she was not aware of the event. Additional info has been requested.
Patient received initial Gardasil 0.5 mL IM left deltoid and noted 10-15 second seizure with loss of consciousness.
Information has been received from a CMA concerning a 50 year old female with a drug allergy to sulfamethoxazole (+) trimethoprim (Bactrim) and sulfa medications who on 11/03/03 was vaccinated IM with a first 0.5mL dose of pneumococcal 23v polysaccharide vaccine (Lot # 647357/0988N). Concomitant therapy included levothyroxine Na (Synthroid), cetirizine hydrochloride (Zyrtec), and mometasone furoate (Nasonex). Subsequently, the pt developed a local reaction that was described as redness and swelling of her arm. The pt went to an urgent care center. A prescription drug was not required. No diagnostic lab studies were performed. It was noted that therapy was discontinued and that the adverse event abated. A product quality complaint was not involved. Follow up information was received from the CMA which indicated that the event was "taken care of with pt." No further information is expected. It was also reported that another female pt was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine and developed a local reaction with a raised, warm and painful injection site (WAES #0311USA01430).
Caregiver states had "headache, lightheadedness, hot flashes, runny nose, SOB, cough" a day after receiving  2nd dose Moderna vaccine.  Info received 02/22/21 when caregiver provided note from her Private MD to return to work.  First dose Moderna 12/30/2020 with no known reaction (info entered into next page although over 1 month in between doses).